El interés en corto de Predictive Oncology da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Predictive Oncology. Los datos de interés en corto se actualizan cada dos semanas.

Predictive Oncology (NASDAQ:POAI) Bolsa, Informe de interés en corto

Predictive Oncology

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Predictive Oncology Inc

Earnings

News

Guidance

NVVE

Nuvve Q4 EPS ($5.75) Up From ($69.80) YoY; Q4 Revenue $1.78M Up From $1.64M YoY

DOGZ

Dogness (Intl) Six-Month EPS $(0.14) Up From $(0.30) YoY, Sales $12.1M Up From $6.7M YoY

RCON

Recon Technology First H1 25 EPS $(2.29) Up From $(8.27) YoY; Revenue $5.8M Down From $6.2M YoY

ReliaQuest Announces It Has Raised More Than $500M In Funding At A Valuation Of $3.4B

General

CMBM

Cambium Networks Files Notification Of Late Filing On Form 12b-25 With Respect to its Annual Report on Form 10-K For Fiscal Year 2024

Late-breaking oral presentation details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGS
Data presentations highlight SPARTAN Study results and real-world case studies of FILSPARI across different IgAN patient backgrounds
Travere Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation (NKF) Spring Clinical Meetings 2025, taking place April 10-13 in Boston, MA.
The late-breaking oral presentation will feature new analyses from the Phase 3 DUPLEX Study of FILSPARI&#xAE; (sparsentan) in focal segmental glomerulosclerosis (FSGS), showing that partial and complete proteinuria remission were achieved earlier and more frequently with FILSPARI than irbesartan, and patients that achieved proteinuria remission had low rates of kidney failure.
The Company will also present data that further explore the role of FILSPARI as a foundational therapy in IgA nephropathy (IgAN). Data from the Phase 2 SPARTAN Study of FILSPARI as first-line treatment in newly diagnosed patients with IgAN demonstrated rapid and sustained reductions in proteinuria, and reductions in sCD163 levels, an inflammatory biomarker associated with kidney injury. Additionally, a presentation of real-world case studies will show FILSPARI's effectiveness across different IgAN patient backgrounds, including those with high proteinuria and prior treatments.
"We look forward to presenting data exploring FILSPARI's potential in FSGS where treatment options remain severely limited, as well as data that reinforce the medicine's clinical benefits in IgAN," said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. "We remain committed to advancing research that supports improved outcomes for people living with rare kidney disease."

TVTX

Travere Therapeutics Announces It Will Present Three Abstracts, Including One Late-Breaking Oral Presentation, At Upcoming National Kidney Foundation Spring Clinical Meetings 2025, Taking Place April 10-13 In Boston, MA

Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) reported quarterly sales of $479.900 million which beat the analyst consensus estimate of $303.479 million by 58.13 percent.

Earnings Beats

NUTX

Nutex Health FY Sales $479.900M Beat $303.479M Estimate

US Nuclear Regulatory Commission Renews Operating Licenses For Duke Energy's Oconee Nuclear Station For An Additional 20 Years

Net loss per share in the full year 2024 was $0.88 on 12.377 million weighted average shares outstanding compared to full year 2023 where the Company delivered a loss of $1.46 per share on 5.429 million weighted average shares outstanding.

OSTX

OS Therapies 2024 EPS $(0.88) May Not Be Comparable To $(1.46) YoY

Biotech

FMC And Bayer Collaborate To Bring Isoflex Active Herbicide Technology To European Markets

Valaris Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) ("Valaris" or the "Company") announced today that it has been awarded a two-year contract offshore West Africa for drillship VALARIS DS-10 that is expected to commence late in the second quarter or in the third quarter 2026. The total contract value for the firm term is $352 million. The total contract value does not include the provision of additional services. The contract includes two unpriced options, each with a duration of one year.
President and Chief Executive Officer Anton Dibowitz said, "This contract award is a testament to the safety and operational performance of VALARIS DS-10 and its crews, which have an excellent track record of successfully executing clients' well programs offshore West Africa. This contract increases our backlog by approximately $350 million and supports our future earnings and cash flow, and we remain focused on securing additional attractive long-term contracts for our high-specification assets."

Contracts

Valaris Awarded Two-Year Contract Award For Drillship VALARIS DS-10

WIIM

ALLR

Allarity Therapeutics shares are trading higher after the company reported FY24 financial results and beat its EPS estimate.

Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn

CARM

Carisma Therapeutics Approved Revised Operating Plan Focusing On Evaluating Strategic Alternatives While Reducing Operational Cash Burn

- Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>), a global leader in photonics, will show a live demonstration of its silicon photonics-based 1.6T-DR8 transceiver module using a Marvell&#xAE; Ara 3nm optical digital signal processor (DSP) at OFC 2025. This transceiver features 200 Gbps electrical and optical interfaces.
While the most advanced DSPs deployed in datacom transceivers today use 5nm node sizes, there is a constant push to an even smaller node size in order to minimize electrical power dissipation. Coherent's transceiver in this demonstration uses Marvell Ara DSP, a 3nm 1.6T PAM4 optical DSP, which aims to reduce the power dissipation of 1.6T optical transceivers by over 20%. Energy efficiency improvement reduces operational costs and enables new AI server and networking architectures to address the need for higher bandwidth and performance for AI workloads within the significant power constraints of the data center. "Demonstrating this next generation of 1.6T transceivers highlights the versatility and robustness of our silicon photonics platform and highlights our strong drive to continually reducing power consumption," said Dr. Jack Xu, Vice President of Engineering for transceivers at Coherent. "As the industry transitions into the era of 200G optical lanes, we remain committed to reinforcing our market leadership by being at the forefront of innovation." &nbsp;

COHR

Coherent Corp To Showcase A Live Demonstration Of Its Silicon Photonics-Based 1.6t-DR8 Transceiver Module Using A Marvel Ara 3NM Optical Digital Signal Processor At OFC 2025

Management

ARDT

Ardent Health Names Dave Caspers As COO

Flexible Solutions Intl (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSI#AMEX">FSI</a>) reported quarterly earnings of $0.24 per share which missed the analyst consensus estimate of $0.39 by 38.46 percent. The company reported quarterly sales of $38.234 million which missed the analyst consensus estimate of $47.685 million by 19.82 percent.

Earnings Misses

Flexible Solutions Intl FY 2025 GAAP EPS $0.24 Misses $0.39 Estimate, Sales $38.234M Miss $47.685M Estimate

Brad Smithy, founding partner and head of wealth management at Elevation Point, believes his firm is uniquely positioned to capitalize on a rapidly evolving financial advisory landscape. The firm aims to redefine success in wealth management.
A New Brand Backed By Decades of Expertise: Speaking with Benzinga at the Future Proof Citywide <a href="https://futureproofhq.com/">event</a> in Miami, Smithy emphasized that while Elevation Point is a new brand, its leadership team is anything but new to the industry. 
&#8220;We have a lot of experience—three of our seven partners have over 90 years combined in wealth management,&#8221; Smithy said.&nbsp;
&#8220;We're not a new firm; we're a new brand built on a strong foundation, and we've already developed an incredible pipeline that has us very optimistic about the future.&#8221;
Read Also: <a href="https://www.benzinga.com/news/events/25/03/44520918/andrew-pitcairn-on-multi-generational-wealth-think-in-50-year-increments">Andrew Pitcairn On Multi-Generational Wealth: &#8216;Think In 50-Year Increments&#8217;</a>
Smithy credits Elevation Point's early success to its commitment to culture, alignment, and long-term relationships. 
&#8220;We love what we do, and we believe in rowing in the same direction,&#8221; he explained. &#8220;If it's good for our clients, it's good for us. That's the philosophy we wake up with every day.&#8221;
Smithy stressed that the firm invests in its employees just as much as it invests in clients. &#8220;We hire people who want to be part of something big,&#8221; he said. &#8220;We feel like we've caught lightning in a bottle, and if we stay true to our vision, the sky&#8217;s the limit.&#8221;
Opportunities in a Changing Industry: Smithy remains bullish on the financial advisory industry despite market volatility and economic uncertainty. 
&#8220;A private equity executive recently told me that we're only in the second inning of a nine-inning game,&#8221; he said. &#8220;That means there's a long way to go and plenty of opportunity for firms like ours.&#8221;
He also underscored the importance of face-to-face interactions in a post-pandemic world. &#8220;COVID reminded us how much we need personal connections,&#8221; he said.
&nbsp;&#8220;Events like Future Proof allow us to strengthen relationships, exchange ideas and drive the industry forward.&#8221;
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Elevation Point &#x7C; Future Proof CityWide Miami 2025" width="500" height="281" src="https://www.youtube.com/embed/07GdSUJQdNc?list=PL_xynMYmeEycXKNjPWkI98N6vKR-7s4D0" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Also:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44542821/inflation-will-accelerate-in-coming-months-if-april-2-tariffs-take-effect-economist-warns">‘Inflation Will Accelerate In Coming Months' If April 2 Tariffs Take Effect, Economist Warns</a></li>
</ul>
Image: Shutterstock

Interview

Elevation Point's Brad Smithy On Building A New Legacy In Wealth Management

TLPH

Talphera shares are trading higher after the company reported a Q4 EPS beat.

GRYP

Gryphon Digital Mining shares are trading higher following a year-over-year increase in Q4 mining revenue.

<a href="https://www.benzinga.com/personal-finance/25/02/43759618/charlie-munger-said-the-hardest-part-of-getting-rich-is-the-first-100000-but-from-there-it-snowballs-and-you-can-ease-off-the-gas">Charlie Munger</a> didn't live to 99 by juicing kale or tracking his steps. The billionaire investor, vice chair of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>, BRK.B)), and famously dry-witted partner of Warren Buffett swore by mental discipline—but when it came to peanut brittle and Diet Coke? He didn't hold back.
Just before his death in November 2023—just shy of turning 100—Munger sat down with <a href="https://www.cnbc.com/2023/11/30/full-transcript-from-cnbcs-charlie-munger-a-life-of-wit-and-wisdom-.html">CNBC's Becky Quick</a> and proved he hadn't lost a step.
"I drink Diet Coke," he said. "I'm sure Diet Coke shortens my life a little. But I don't give a damn… It's only the good part of life I want anyway. And Diet Coke may be helping me skip it. But who knows? It's helping me skip the last month, not the first month."
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>
That's Munger in a can: brutally honest, self-aware, and sharper than most people half his age.
While most wellness gurus preach moderation like it's a religion, Munger took a slightly different angle. He loved sweets—especially peanut brittle—and told Quick <a href="https://x.com/CNBC/status/1625950398593830925">in February 2023</a> with a grin, "That's what you want to do if you want to live to be 99." He wasn't joking, either. He even joked about "advertising my own product," since his favorite brittle came from See's Candies, a Berkshire Hathaway company.
But this wasn't reckless indulgence. Munger didn't binge. He just didn't believe in punishing himself for the sake of squeezing out a few extra, joyless years. He famously avoided exercise—"I've done almost no exercise on purpose in my life," he said, unless he actually enjoyed the activity, like tennis. "For the first 99 years, I've gotten by without doing any exercise at all."
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Still, Munger wasn't oblivious to health. He once lost an eye after a botched surgery. He used a wheelchair in his final years. He outlived a son. He survived a divorce. He knew suffering. And yet, he maintained his mental clarity and signature bite right to the end.
His long life sparked curiosity about whether he was what <a href="https://www.feinberg.northwestern.edu/research/podcast/what-makes-someone-a-superager.html">researchers call a "SuperAger"</a>—someone over 80 who retains the cognitive sharpness of someone decades younger. While some studies tie SuperAging to active lifestyles and brain-friendly routines, they also show that it's not always about eating clean or running marathons. Strong relationships and mental engagement matter more—and Munger had those in spades.
Even in his final year, he stayed plugged in via Zoom, connecting with colleagues and fans alike. He spoke at <a href="https://careers.zoom.us/zh/blogs/zoomblog/highlights-and-helpful-advice-our-zoomtopia-closing-keynote-with-charlie-munger">Zoomtopia in October 2023</a> and, according to <a href="https://markets.businessinsider.com/news/stocks/charlie-munger-zoomtopia-keynote-buffett-berkshire-crypto-ai-bitcoin-investing-2023-10">analyst Melody Brue</a>, delivered a gem about donuts: they're not good for you, but if you're disciplined, you can enjoy them now and then.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
That was the real secret. Munger didn't obsess over health. He obsessed over avoiding stupidity. "My game in life was always to avoid all standard ways of failing," he told Quick. "You teach me the wrong way to play poker and I will avoid it."
And maybe that's how you make it to 99 with your mind intact and <a href="https://www.benzinga.com/24/11/42115069/warren-buffett-is-set-to-collect-776-million-in-coca-cola-dividends-but-daughter-says-his-wife-buys-him-the-soda-on-sale">your Diet Coke in hand</a>: avoid the obvious mistakes, don't take life too seriously, and treat yourself to the things you love—even if they come in a can with aspartame.
Because, as Munger put it: "It's only the good part of life I want anyway."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>

Personal Finance

Charlie Munger Lived To 99 And Refused To Give Up His Favorite Soda —'I'm Sure Diet Coke Shortens My Life a Little, But I Don't Give a Damn'

Press Releases

Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Small Cap

Opinion

Investors Eye Biotech Sector as Cancer Therapy Market Surges

Predictive Oncology Closes Registered Direct Offering

Merger Agreement with BioSymetrics to Accelerate Biomarker Identification, Enhance Drug Discovery and Expand Precision Medicine Applications in Advanced Cancer Diagnosis and Treatment

Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Milestone Merger Payment made with Predictive Oncology to Advance AI-Driven Biomarker Discovery and Precision Medicine in Cancer and Beyond: Renovaro, Inc. (NASDAQ: RENB)

Health Care

Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries

Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

Breakthroughs and Discoveries: TNON, PNPN.V, POAI, DYAI, PRSO, Drive Innovation Across Sectors

Comments

Predictive Oncology

Interés en corto

Predictive Oncology (NASDAQ:POAI) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL